306 results about "Combination Medication" patented technology

The invention discloses a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The composition comprises an IGF2BP3 inhibitor and a platinum chemotherapeutic drug. According to the combined medication scheme, the IGF2BP3 function is inhibited to block an ATF4 survival promoting signal channel mediated by the IGF2BP3 function, a synergistic effect is generated with a DNA damage mechanism of platinum drugs, the anti-tumor effect can be remarkably enhanced, chemotherapy drug resistance can be effectively reversed, toxic and side effects are expected to be reduced, and the application prospect is wide. And a new strategy is provided for overcoming the treatment problem of the non-small cell lung cancer, especially platinum-resistant non-small cell lung cancer.

The invention belongs to the field of biological medicines, and finds and verifies that taquinimod or pharmaceutically acceptable salts thereof can be used for preparing medicines for treating endometriosis for the first time, and is particularly suitable for progestogen-resistant, recurrent or deep infiltration type endometriosis. The action mechanism of the taquinimod is as follows: the taquinimod can down-regulate the expression of S100A9 protein and reduce the infiltration of S100A9 + macrophages by inhibiting an NF-kappa B signal channel so as to further inhibit the expression of a vascular endothelial growth factor receptor 1 (VEGFR1) and a matrix metalloproteinase 2 (MMP2), finally block pathological angiogenesis and inhibit the growth of ectopic lesions. Animal experiments show that the taquinimod can significantly reduce the number and weight of nidus of a mouse model with endometriosis. The invention provides a brand-new non-hormone treatment choice with a clear action mechanism for clinical application, provides a pharmaceutical composition containing a specific dosage and a drug combination scheme, and has an important clinical value.

Relacorilant is useful in the treatment of hypercortisolism and cancer. Many drugs useful in treating hypercortisolism or cancer are metabolized by CYP2C9 enzymes. The effects of concomitant administration of relacorilant and a CYP2C9 substrate are disclosed herein.Relacorilant potently inhibited CYP2C9 in an in vitro test, indicating that co-administration of relacorilant and a CYP2C9 substrate would be expected to increase the CYP2C9 substrate plasma exposure more than five-fold in vivo. Significant reductions in CYP2C9 substrate doses would be expected to be required when administered with relacorilant.Surprisingly, no such increase in plasma exposure was seen in human studies. Applicant discloses that relacorilant may be safely co-administered with unmodified doses of a CYP2C9 substrate such as, e.g., tolbutamide, glimepiride, and glipizide. Relacorilant and unmodified doses of CYP2C9 substrate such as tolbutamide, glimepiride, and glipizide may be co-administered to treat hypercortisolism, or may be co-administered to a cancer patient.

The invention provides a combined medicine recommendation method based on multi-modal alignment. A core module of the recommendation method comprises a cloth perception multi-modal medicine alignment module, a time sequence multi-view patient aggregation module and a combined medicine recommendation module. According to the recommendation method, electronic health records EHRs serve as a data source, multi-modal information matched with physical signs of a patient and medicine application characteristics is obtained, effective alignment and fusion are conducted on the multi-modal information through the core module, and suggestion data matched with the multi-modal information and composed of multiple medicines are generated. A DDI loss function and a dynamic weighting strategy are introduced to process conflicts among different drugs in the generated suggestion data so as to output safe suggestion data, and it is avoided that conflicting drugs are recommended in the suggestion data; according to the method, personalized, high-safety, scientific and reasonable drug combination suggestions can be provided.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

The invention discloses a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia and application, and relates to the technical field of biomedicine. The invention provides a combined pharmaceutical composition for preventing, relieving or treating acute myelogenous leukemia. The combined pharmaceutical composition comprises vincristine and cytarabine or pharmaceutically acceptable salts and solvates of the vincristine and the cytarabine. According to the vincristine and cytarabine combined pharmaceutical composition, the apoptosis level of acute myelogenous leukemia cells can be remarkably improved, and compared with single-drug treatment, the vincristine and cytarabine combined pharmaceutical composition has higher anti-tumor efficacy; vincristine interferes or blocks a cell senescence state induced by cytarabine through a microtubule destruction effect, so that the problem of drug insensitivity caused by cell senescence is solved, and drug resistance caused by cell senescence is effectively reversed.

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

The invention relates to the technical field of biochemistry, and particularly discloses a galactosyl zinc-porphyrin derivative and a preparation method and application thereof.The galactosyl zinc-porphyrin derivative is formed by coupling a group with double functions of fluorescence and cytotoxic activity and a liver cancer targeting group, can be specifically combined with a liver cancer cell HepG2, emits 608 nm and 659 nm fluorescence signals under the excitation wavelength of 425 nm, and can be used for detecting liver cancer. And accurate tracing can be realized. Meanwhile, IC509.1 mu M + / -2.59 is used for killing liver cancer cells, so that targeted therapy is realized. The chemical disclosed by the invention has the functions of fluorescence tracing and targeted killing, can synchronously realize accurate positioning (fluorescence tracing) and efficient removal (targeted treatment) of liver cancer cells without drug combination, can be used for liver cancer diagnosis, treatment and curative effect evaluation, and has extremely high research and development value.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

Disclosed in the present invention is a combined pharmaceutical composition for treating tumors, comprising a chemotherapeutic drug and at least one compound represented by formula (I). The compound has the effect of enhancing the efficacy of the chemotherapeutic drug, thereby reducing the dose of the chemotherapeutic drug and diminishing its toxic and side effects.

The invention provides a method for treating AR negative TNBC through combination of quercetin and enzalutamide, the quercetin up-regulates the AR expression level by inhibiting a high-expression solute carrier SLC7A5, so that tumor cells which are not sensitive to enzalutamide originally obtain drug sensitivity again; the combined use of an AR antagonist enzalutamide (1-80 [mu] M) can cooperatively block an AR signal channel and significantly inhibit cell proliferation (the inhibition rate of drug combination is 70%, Plt, 0.01 higher than that of a single drug). In-vitro experiments prove that the scheme has a synergistic effect (the effect is optimal when the mass ratio is 1: 1-5: 1) in MDA-MB-231 cells, and an animal model shows that the tumor volume inhibition rate reaches 70% or above. Safety evaluation shows that the drug combination does not cause abnormity of serum biochemical indexes (ALT / AST / BUN / CREA) or damage of main organs and tissues. The invention further provides a preparation method of an oral preparation (tablets / capsules / nanoparticles) containing quercetin (50-500 mg / day) and enzalutamide (40-160 mg / day), and a new strategy is provided for reversing AR-TNBC drug resistance.

This invention relates to the application of mitochondrial extracts in reversing drug resistance in solid tumors. By combining mitochondrial extracts with chemotherapeutic drugs, the resistance of chemotherapeutic-resistant solid tumors to these drugs can be reversed. Compared to using mitochondrial extracts and chemotherapeutic drugs alone, this method effectively enhances drug efficacy, thereby overcoming chemotherapeutic resistance in solid tumors. This invention, through intervention with mitochondrial extracts in different chemotherapeutic-resistant solid tumor cell lines, has verified that the combined use of mitochondrial transplantation and chemotherapeutic drugs can reverse chemotherapeutic resistance, thereby improving the efficacy of chemotherapy and opening up the possibility of continued treatment for patients with advanced solid tumors who are resistant to chemotherapeutic drugs.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

This application relates to the fields of chemistry and biomedicine, specifically to a tofenamic acid lipid composition, its preparation method, and its application. A tofenamic acid derivative is obtained by reacting a morpholine solution with tofenamic acid, ethyldimethylaminopropylcarbodiimide, and 4-dimethylaminopyridine, followed by purification. The morpholine in the morpholine solution is an N-alkylmorpholine compound. The tofenamic acid derivative is used to prepare tofenamic acid prodrug liposomes via ethanol injection, which are then used in combination with a STING agonist. The synergistic effect of the combined treatment stems from the dual regulation of the tumor immune microenvironment (TME), overcoming the immune escape induced by STING monotherapy. After STING agonist treatment, the intratumoral COX-2 / PGE2 axis is activated, leading to immunosuppression. The combination of tofenamic acid liposomes and a STING agonist inhibits COX-2, thus relieving this negative feedback loop.

The invention discloses an anti-tumor pharmaceutical composition with a synergistic effect and application thereof, the composition is composed of cis-platinum and atorvastatin, and the molar ratio of the cis-platinum to the atorvastatin is 1: 1.5; the invention provides a different drug concentration ratio scheme for treating cancer cells, inhibiting proliferation and activation of cancer cells and inducing apoptosis of the cancer cells by drug combination at low drug concentration, and compared with a traditional scheme, the scheme weakens drug resistance of the cells, and has the advantages of lower concentration, safer and more effective drug concentration ratio and higher safety. The toxic reaction of an organism caused by high-concentration drugs is weakened.

The present disclosure provides methods related to the co-administration of a cytochrome P4503A4 (CYP3A4) inhibitor and Compound A (azetukalner). The combination of the CYP3A4 inhibitor and azetukalner is useful in the treatment and / or prevention of diseases, disorders, and conditions (e.g., diseases, disorders, and conditions associated with Kv7 potassium channel dysfunction).

The application provides a combined drug, a liposome, a biomimetic liposome, a preparation method of the combined drug, the liposome and the biomimetic liposome, and application of the combined drug, the liposome and the biomimetic liposome in preparation of an anti-breast cancer lung metastasis drug, and belongs to the technical field of biological medicines. The combined drug comprises panatinib and ginsenoside Rg3. The application further provides a liposome PNT-Rg3-Lipo for simultaneously loading the two, and a biomimetic liposome MM / PNT-Rg3-Lipo coated with a macrophage membrane. Experiments show that the combination of the two can synergistically regulate chemokines CXCL1 , CXCL2 and CXCL11 , and the effect is better than the sum of the single use. The MM / PNT-Rg3-Lipo has uniform particle size, retains integrin alpha 4 / beta 1 functional proteins, can target lung metastases, significantly reduces metastatic nodules, and has good biocompatibility. The application provides an effective new strategy for resisting breast cancer lung metastasis.

This invention discloses a trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its applications. The siRNA molecule consists of a sense strand and an antisense strand, which are anti-complementary to form a double-stranded RNA structure. Each of the sense and antisense strands independently contains two pendant deoxythymidines at its 3' end. The nanomedicine uses trimethyl chitosan as its core framework, efficiently encapsulating the siRNA molecule through electrostatic interactions, and then modifying hyaluronic acid through electrostatic interactions to form core-shell structured nanoparticles. This invention forms a complete technology chain from target validation, siRNA sequence design, nanodelivery system construction, in vivo and in vitro efficacy verification to the development of combination drug strategies. It also provides quantifiable efficacy evaluation biomarkers, offering a clear basis for clinical patient screening and efficacy monitoring.

The invention discloses a combined medicine composition of a thyroid Qixia patch and a selenium yeast tablet and application of the combined medicine composition, and belongs to the technical field of medicines. The composition is composed of a thyroid and astragalus mongholicus summer patch and a selenium yeast tablet, the thyroid and astragalus mongholicus summer patch is prepared by grinding astragalus mongholicus, selfheal, radix clematidis, turmeric, airpotato yam and semen brassicae as raw materials, and adding vaseline to prepare paste. The selenium yeast tablet is used for oral administration and is matched with the thyroid qi-summer patch for external application on the neck, and the treatment course is 3 months. Clinical verifications show that the total effective rate of the composition reaches 87.80%, the composition can effectively improve symptoms such as anterior cervical mass, dysphoria, irritability and the like, reduce the level of serum TPOAb, reduce thyroid and nodule volumes and improve nodule blood flow, the safety is good, the curative effect is superior to that of pure western medicine treatment, and an effective treatment scheme is provided for related diseases.

The invention relates to application of a GSTP1 inhibitor in preparation of a medicine for treating chronic myelogenous leukemia, and belongs to the technical field of biomedicine. According to the application, it is found for the first time that interaction exists between CML core driving proteins BCR-ABL1 and GSTP1, GSTP1-mediated BCR-ABL1 protein glutathione modification can be effectively inhibited through targeted inhibition of the expression level of the GSTP1, the stability of the BCR-ABL1 protein is reduced, CML cell proliferation is inhibited, and CML cell apoptosis is promoted, so that the effect of treating the chronic myeloid leukemia is achieved. Therefore, the GSTP1 can be used as a treatment target, the GSTP1 inhibitor Ezatiostat is used for preparing the medicine for treating the chronic myelogenous leukemia, a theoretical basis and possibility are provided for developing a GSTP1 inhibitor and TKI combined medication scheme in the future, synergistic interaction is expected, and prognosis of a patient is further improved.

The present disclosure relates to methods of treating cancers comprising coadministration of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, to a patient in need thereof. Also disclosed are pharmaceutical compositions of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, for use in such cancer treatment, as well as uses of these compounds for manufacture of medicaments for the treatment of cancers.

The application discloses a composition containing a peripheral vasodilator and a 5alpha-reductase inhibitor, effectively solves the transdermal inhibition of the peripheral vasodilator on the 5alpha-reductase inhibitor by adding a specific penetration enhancer, improves the transdermal rate of the active ingredients in the pharmaceutical composition by proportion adjustment, greatly improves the synergistic effect of local combined medication, avoids the side effects brought by oral 5alpha-reductase inhibitor, and improves the safety of the medicine.

The present application relates to the technical field of artificial intelligence, and particularly relates to an individualized medication prediction method based on artificial intelligence, comprising: acquiring a plurality of standard historical medical data sets; acquiring metabolic capacity scores and drug metabolism rates corresponding to all data groups; training to obtain relationship models corresponding to all standard historical medical data sets; acquiring liver metabolism parameters, gene expression parameters and each drug name in a treatment scheme of a patient to obtain a drug metabolism rate; and determining a corresponding prediction drug amount determination method according to whether the drug types in the treatment scheme have a competitive relationship. The present application integrates drug metabolism enzyme-related gene expression and liver metabolism function, simultaneously incorporates drug absorption competition and metabolism enzyme competition when drugs are used in combination, corrects the final output prediction drug amount when drugs are used in combination, so that the model is more suitable for the actual drug use scene, and the accuracy of the prediction result is increased.

This invention provides a drug interaction prediction method based on a bidirectional cross-view attention network, belonging to the field of drug interaction prediction technology. The method first constructs a Morgan fingerprint similarity view of the drug, an original DDI view, and a multi-scale diffusion view based on personalized PageRank. Then, a graph convolutional network with shared weights is used to co-encode the multiple views, generating a unified drug embedding representation. Finally, a bidirectional cross-view attention mechanism is used to achieve fine-grained interaction and alignment between the structural and attribute views, and interaction prediction is completed via a multilayer perceptron. This invention effectively alleviates the sparsity problem of the DDI network through multi-scale topology enhancement and achieves complementary enhancement between views using bidirectional cross-view attention, significantly improving the accuracy and generalization ability of drug interaction prediction. It can provide reliable technical support for drug development screening and clinical combined drug safety assessment.

The present invention relates to a composition for preventing, alleviating or treating metabolic diseases, the composition comprising a rosuvastatin and ursodeoxycholic acid conjugate or a pharmaceutically acceptable salt thereof, in which the statin conjugates to an ursodeoxycholic acid transporter and has the effects of function inhibition, cholesterol level reduction, antilipid toxicity, body weight reduction, blood lipid reduction, fatty liver alleviation, inflammation alleviation, and kidney damage alleviation. The composition, in the form of a single formulation, has the characteristics of maintaining the therapeutic effects of rosuvastatin and ursodeoxycholic acid while reducing the side effects of existing statins, and thus can be widely used as a substitute for complex formulations in the treatment of metabolic diseases.

The application discloses application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and the antifungal drugs, and relates to the technical field of antifungal drugs. It is found through systematic in-vitro drug sensitivity test that natural product gynostemma pentaphyllum saponin H combined with specific azole antifungal drugs (especially posaconazole POS) can produce significant synergistic antifungal effect, especially for clinical thorny aspergillus, candida, new cryptococcus and dark fungi. The combination strategy can significantly reduce the minimum inhibitory concentration of azole drugs, reverse drug resistance, and is effective for multi-drug resistant strains (such as candida auris). The application provides an efficient and low-toxicity new combination drug scheme for overcoming the increasingly serious fungal drug resistance problem.

The application belongs to the technical field of biological medicine, and provides application of combined use of tocopherol and mulberroside C in preparation of a drug for treating liver cancer, which is combined use of tocopherol and mulberroside C in preparation of a drug for treating liver cancer. Through in-vitro cell experiments, the growth inhibition effect of tocopherol and mulberroside C on liver cancer cells is evaluated; the results show that tocopherol and mulberroside C can inhibit the growth activity of liver cancer cells to achieve the purpose of treating liver cancer.

The invention provides a drug-loaded gelatin nanogel, a bionic nanogel, a preparation method of the drug-loaded gelatin nanogel, a preparation method of the bionic nanogel, a combined drug and application of the bionic nanogel, and belongs to the technical field of biological medicine. According to the invention, all-transretinoic acid, pirfenidone and gelatin react to form drug-loaded gelatin nanogel, and the drug-loaded gelatin nanogel can synergistically inhibit the activation of pancreatic stellate cells and block a fibrosis-promoting signal channel, so that the reversion of a pancreatic cancer fibrosis microenvironment is realized; meanwhile, the activated pancreatic stellate cell membrane is coated with the drug-loaded gelatin nanogel to construct the bionic nanogel, so that the bionic nanogel has active targeting property, and the delivery efficiency and the treatment effect of the drug are remarkably improved; and the drug-loaded gelatin nanogel, the bionic nanogel and the chemotherapeutic drug are combined for treating pancreatic cancer, so that a remarkable anti-tumor effect is achieved, and the combined treatment of the bionic nanogel and gemcitabine has a synergistic anti-tumor effect. The gel provided by the invention realizes effective regulation and control of a pancreatic cancer dense fibrosis microenvironment, and provides a feasible new strategy for treatment of pancreatic cancer.

Novel methods are disclosed for treating patients with Parkinson's disease and other primary and secondary parkinsonian disorders by improving cell engraftment. Treating patients with antihyperlipidemic drugs and / or CSF-1R antagonists before, during, and / or after transplantation of DA neurons improves cell viability, engraftment, proliferation, migration, or differentiation of the administered DA neurons. Methods are disclosed for pre-treating patients to improve engraftment of administered cells. Methods are disclosed for pre-treating patients to improve engraftment of administered progenitor cells.

The present application relates to the technical field of biological pharmacy, in particular to a combined drug for treating colitis and application thereof, wherein the volume ratio of Coptis exosome and Salmonella outer membrane vesicle in the combined drug is 1-2:1-3; the concentration of the Coptis exosome and the Salmonella outer membrane vesicle is 9-11 mg / mL. The present application overcomes the limitation of single treatment strategy by innovatively combining the Coptis exosome and the Salmonella outer membrane vesicle, significantly improves the treatment effect, and avoids the side effects of existing drugs. The present application has lower treatment cost, is safer and has no drug resistance problem, and can provide a more effective, safe and economical treatment method for inflammatory diseases such as colitis.